Overview
- Across two annual screening rounds in 2,978 women with dense breasts, supplemental molecular breast imaging found 6.7 additional cancers per 1,000 screens in year one and 3.5 per 1,000 in year two.
- MBI-only findings included 30 lesions in 29 participants, 71% of which were invasive with a median size of 0.9 cm, and 90% were node-negative while 20% were node-positive.
- In detecting node-positive disease, DBT alone found 4 of 7 cases in the first round versus 7 of 7 with DBT plus MBI, and 1 of 6 in the second round versus 4 of 6 with the combined approach.
- Recall rates rose modestly with the addition of MBI, from 8.6% to 17.9% in year one and from 8.9% to 13.8% in year two, with lower recalls on the second round as prior MBI images were available.
- The multicenter Density MATTERS trial used technetium-99m sestamibi–based imaging across academic and community sites, included 12% minority enrollment, and was published in Radiology.